US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alto Neuroscience

2.26

+0.01000.44%

Post-market: 2.25-0.0100-0.44%16:58 EDT

Volume:148.83K

Turnover:332.58K

Market Cap:61.18M

PE:-0.91

High:2.27

Open:2.19

Low:2.15

Close:2.25

Loading ...

Overview Company News Filings

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

Press Release: Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

Alto Neuroscience Strengthens Financial Position Amid Increased R&D

Alto Neuroscience price target lowered to $10 from $32 at Stifel

Alto Neuroscience Q3 2024 GAAP EPS $(0.62) Beats $(0.65) Estimate

Press Release: Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout

Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform

Wedbush Downgrades Alto Neuroscience to Neutral From Outperform, Adjusts Price Target to $4 From $29

MT Newswires Live

Alto Neuroscience falls -62.8%

Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss

Sector Update: Health Care Stocks Steady Premarket Wednesday

MT Newswires Live

Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Investors Look Ahead to Economic Data as US Futures Decline Pre-Bell

MT Newswires Live

Alto Neuroscience, Inc. (ANRO) Gets a Buy from Stifel Nicolaus

Alto Neuroscience Is Maintained at Outperform by Baird

Alto Neuroscience downgraded to Neutral from Buy at Rodman & Renshaw

Alto Neuroscience price target lowered to $10 from $32 at Baird

Alto Neuroscience Says Phase 2b Study in Major Depressive Disorder Fails to Meet Primary Endpoint

MT Newswires Live

Alto Neuroscience Shares Plunge After ALTO-100 Study Misses Primary Endpoint

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ANRO/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"ANRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","market":"US","secType":"STK","nameCN":"Alto Neuroscience","latestPrice":2.26,"timestamp":1744920000000,"preClose":2.25,"halted":0,"volume":148826,"hourTrading":{"tag":"盘后","latestPrice":2.25,"preClose":2.26,"latestTime":"16:58 EDT","volume":2704,"amount":6110,"timestamp":1744923514349},"delay":0,"floatShares":19503522,"shares":27072129,"eps":-2.496992,"marketStatus":"Market Closed","change":0.01,"latestTime":"04-17 16:00:00 EDT","open":2.19,"high":2.27,"low":2.15,"amount":332576.28305519995,"amplitude":0.053333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.496992,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1706850000000,"exchange":"NYSE","adjPreClose":2.25,"postHourTrading":{"tag":"盘后","latestPrice":2.25,"preClose":2.26,"latestTime":"16:58 EDT","volume":2704,"amount":6110,"timestamp":1744923514349},"volumeRatio":0.49232009004342253,"impliedVol":1.8281,"impliedVolPercentile":0.2055},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","floatShares":19503522,"roa":"-32.46%","roe":"-55.19%","lyrEps":-2.496992,"volumeRatio":0.49232009004342253,"shares":27072129,"dividePrice":0,"high":2.27,"amplitude":0.053333,"preClose":2.25,"low":2.15,"week52Low":1.6,"pbRate":"0.40","week52High":17.55,"institutionHeld":0,"latestPrice":2.26,"eps":-2.496992,"divideRate":0,"volume":148826,"delay":0,"ttmEps":-2.496992,"open":2.19,"prevYearClose":4.23,"prevWeekClose":2.13,"prevMonthClose":2.16,"prevQuarterClose":2.16,"fiveDayClose":2.05,"twentyDayClose":2.69,"sixtyDayClose":4.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANRO\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2490854129","title":"Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology","url":"https://stock-news.laohu8.com/highlight/detail?id=2490854129","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490854129?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:03","pubTimestamp":1733922180,"startTime":"0","endTime":"0","summary":"– Data generated from Alto’s precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion –。– New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for patient selection –。– An interim analysis will be conducted for the ongoing Phase 2b trial of ALTO-300 as an adjunctive treatment in MDD; results from the interim analysis are expected in the first quarter of 2025, followed by topline data from the complete study sample in the first half of 2025 –","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nlv57F6zxTB8SR91fcBKMw--~B/aD01Mzc7dz0xNjU5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cb0c9c80f60417ff34072d58865a1f4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nlv57F6zxTB8SR91fcBKMw--~B/aD01Mzc7dz0xNjU5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cb0c9c80f60417ff34072d58865a1f4e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alto-neuroscience-announces-data-presented-130300504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0289739699.SGD","LU1059921491.USD","IE00BSNM7G36.USD","AFG","IE00B19Z3581.USD","BK4107","BK4117","LU0058720904.USD","ABVC","BK4139","LU1261432733.SGD","LU0868494617.USD","BK4007","IE00B19Z3B42.SGD","BK4588","BK4196","ANRO","IE0002270589.USD","CI","BK4585"],"gpt_icon":0},{"id":"2486315793","title":"Press Release: Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2486315793","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486315793?lang=en_us&edition=fundamental","pubTime":"2024-11-28 21:06","pubTimestamp":1732799160,"startTime":"0","endTime":"0","summary":"Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline. \"Since our company's inception a little over a year ago, AllinkBio has rapidly advanced from lead asset PCC to clinical development stage,\" said Hui Feng, Ph.D., Founder and Chief Executive Officer of AllinkBio. \"We are grateful for the continued support from existing shareholders and delighted to welcome new investors who recognize both our scientific excellence and capability of translating scientific findings into clinical applications. Their support enables us to accelerate the development of our diverse pipeline spanning multiple modalities including next-generation ADCs and bispecific antibodies targeting oncology and immunology diseases. Looking ahead, we are poised to achieve multiple pipeline milestones in the coming months as we pursue our long-term mission of bringing innovative therapeutics to patients with significant unmet medical needs.\". \"We ar","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","HK0000320264.USD","QLD","LU0048580855.USD","SQQQ","HK0000306701.USD","ANRO","NEX.SI","BK4173","LU1988902786.USD","LU0572944931.SGD","IE00B29SXG58.USD","LU1969619763.USD","HUYA",".IXIC","WDH","LU0633140727.USD","LU1868837565.USD","688316","LU0633140560.USD","LU2242644610.SGD","IE00B0JY6N72.USD","LU0594300179.USD","QID","BZ","EVS.SI","BK4077","688169","AAQC","LU1719994722.HKD","LU0456827905.SGD","LU0589944569.HKD","TQQQ","LU1303224171.USD","BK4099","MNQmain","SG9999002463.SGD","LU0072462343.USD","LU1048588211.SGD","LU0823038988.USD","LU0516422366.SGD","LU0823426480.USD","ADC","LU0455707207.USD","NQmain"],"gpt_icon":1},{"id":"2483180378","title":"Alto Neuroscience Strengthens Financial Position Amid Increased R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2483180378","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483180378?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:44","pubTimestamp":1731559469,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc. ( ($ANRO) ) has released its Q3 earnings. Here is a breakdown of the information Alto Neuroscience, Inc. presented to its i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-strengthens-financial-position-amid-increased-rd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-strengthens-financial-position-amid-increased-rd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2483010190","title":"Alto Neuroscience price target lowered to $10 from $32 at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2483010190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483010190?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:33","pubTimestamp":1731501191,"startTime":"0","endTime":"0","summary":"Stifel lowered the firm’s price target on Alto Neuroscience (ANRO) to $10 from $32 and keeps a Buy rating on the shares. The firm notes its lowered...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-price-target-lowered-to-10-from-32-at-stifel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-price-target-lowered-to-10-from-32-at-stifel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","ANRO"],"gpt_icon":0},{"id":"2483065165","title":"Alto Neuroscience Q3 2024 GAAP EPS $(0.62) Beats $(0.65) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483065165","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483065165?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:12","pubTimestamp":1731449552,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.65) by 4.62 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41923296/alto-neuroscience-q3-2024-gaap-eps-0-62-beats-0-65-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alto Neuroscience Q3 2024 GAAP EPS $(0.62) Beats $(0.65) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2483105732","title":"Press Release: Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483105732","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483105732?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:10","pubTimestamp":1731445800,"startTime":"0","endTime":"0","summary":"-- Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients with anhedonia --. -- Additional Phase 2 studies ongoing: ALTO-101 in schizophrenia and ALTO-100 as an adjunctive treatment in bipolar depression --. -- Key learnings from ALTO-100 Phase 2b MDD trial including clinically meaningful effect observed in a pre-specified secondary analysis and evidence of stratification using the pre-specified enrichment biomarker in patients with confirmed drug compliance --. -- Strong cash position of approximately $182 million is expected to fund planned operations into 2027, and through at least four additional clinical study readouts --. Alto Neuroscience, Inc.   a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2024, and highlighted","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","ANRO","CIAS","BK4007","BK4139"],"gpt_icon":0},{"id":"2477162638","title":"Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2477162638","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477162638?lang=en_us&edition=fundamental","pubTime":"2024-10-24 20:32","pubTimestamp":1729773122,"startTime":"0","endTime":"0","summary":"As previously reported, Wedbush analyst Laura Chico downgraded Alto Neuroscience  to Neutral from Outperform with a price target of $4, down from $29. With the Phase 2b ALTO-100 readout in major depressive disorder, or MDD, missing its primary endpoint, the firm gives credit to Alto for conducting an ambitious program. Nevertheless, Wedbush is removing ALTO-100 from its estimates. The absence of a positive efficacy signal suggests the biomarker approach may require further investigation before yielding a workable strategy. Following the update, the firm is also increasing its valuation discount rate and removing net cash from its valuation. On the plus side, Alto holds two readouts in the first half of 2025 in MDD. However, these remain upside to Wedbush’s estimates. The firm’s Alto valuation derives solely from ALTO-101 in schizophrenia with data expected in the second half of 2025.Alto Neuroscience downgraded to Neutral from Outperform at Wedbush. Alto Neuroscience downgraded to Neut","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gzgF9t_mQ6p_koEbXiNReQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ea7d93919fc9da6c2816cb36023ae54f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gzgF9t_mQ6p_koEbXiNReQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ea7d93919fc9da6c2816cb36023ae54f"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/wedbush-downgrades-alto-neuroscience-neutral-123202079.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wedbush-downgrades-alto-neuroscience-neutral-123202079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALTO","ANRO"],"gpt_icon":0},{"id":"2477552330","title":"Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2477552330","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477552330?lang=en_us&edition=fundamental","pubTime":"2024-10-24 01:36","pubTimestamp":1729704986,"startTime":"0","endTime":"0","summary":"On Tuesday, Alto Neuroscience, Inc.  revealed that the Phase 2b study of ALTO-100 for major depressive disorder  did not meet its primary endpoint compared to placebo.The biomarker-defined major depressive disorder patient group treated with ALTO-100 did not demonstrate a statistically significant improvement in depressive symptoms compared to placebo.ALTO-100 did not demonstrate a benefit over the placebo on the pre-specified key secondary analyses.Also Read: Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape.The analyst is now focused on the upcoming ALTO-300 Phase 2b results in major depressive disorder , anticipated in the first half of 2025, for further insights.“While data points draw increased scrutiny on the biomarker stratification approach, historically placebo-controlled MDD studies have been high-risk, and this one appears no different. Still, in our discussions with management, it remained confident in the ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/srUMf7Ait4tgdlTsCxqr4w--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/67bdb4f80cf0974512e8a38d14d8a456","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/srUMf7Ait4tgdlTsCxqr4w--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/67bdb4f80cf0974512e8a38d14d8a456"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuropsychiatry-focused-alto-neurosciences-mid-173626131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ABVC","ANRO","BK4139","SSI"],"gpt_icon":0},{"id":"2477510655","title":"Wedbush Downgrades Alto Neuroscience to Neutral From Outperform, Adjusts Price Target to $4 From $29","url":"https://stock-news.laohu8.com/highlight/detail?id=2477510655","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477510655?lang=en_us&edition=fundamental","pubTime":"2024-10-23 23:27","pubTimestamp":1729697226,"startTime":"0","endTime":"0","summary":"Price: 4.45, Change: -10.08, Percent Change: -69.37","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANRO"],"gpt_icon":0},{"id":"2477154536","title":"Alto Neuroscience falls -62.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477154536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477154536?lang=en_us&edition=fundamental","pubTime":"2024-10-23 21:50","pubTimestamp":1729691445,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (ANRO) is down -62.8%, or -$9.13 to $5.40. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-falls-62-8?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-falls-62-8?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2477533045","title":"Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2477533045","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477533045?lang=en_us&edition=fundamental","pubTime":"2024-10-23 21:50","pubTimestamp":1729691400,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/10/41489449/dow-tumbles-over-250-points-boeing-posts-q3-loss","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139",".IXIC","PCOM","QLD","LRHC","BK4575","BK4579","SQQQ","ANRO","BK4134","BK4534","LU0321505439.SGD","IBM","LU0321505868.SGD","BK4079","LU1883839398.USD","BK4583","NQmain","PSQ","APVO","LU2326559502.SGD","BK4564","CNSP","MNQmain","BK4187","BK4007","BK4533","TQQQ","LU1430594728.SGD","LU1880398471.USD","BK4122","LU0868494617.USD","BK4588","BK4175","BK4585","QID","BK4551","BK4516","VRAX","BA","LU1429558221.USD","BK4538","LU1880398554.USD","LU1435385759.SGD","LU1585245621.USD"],"gpt_icon":1},{"id":"2477408587","title":"Sector Update: Health Care Stocks Steady Premarket Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2477408587","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477408587?lang=en_us&edition=fundamental","pubTime":"2024-10-23 21:15","pubTimestamp":1729689320,"startTime":"0","endTime":"0","summary":"Health care stocks were steady premarket Wednesday with the iShares Biotechnology ETF  and Health Care Select Sector SPDR Fund  recently inactive.Alto Neuroscience  shares tumbled by over 62% after the company said a phase 2b study of ALTO-100 in patients with major depressive disorder failed to meet its primary endpoint compared with placebo.Evotec  shares were almost 8% higher after the company said it will receive a $50 million payment as part of its partnership with Bristol Myers Squibb  to develop a molecular glue-based pipeline.Thermo Fisher Scientific  shares were down almost 2% after the company reported Q3 adjusted earnings of $5.28 per diluted share, down from $5.69 a year earlier.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0122379950.USD","IBB","BK4121","EVO","XLV","LU1923622291.USD","LU2242646821.SGD","LU0061474960.USD","LU1720051108.HKD","LU1571399168.USD","LU1623119135.USD","LU0957791311.USD","LU0985481810.HKD","LU2125154778.USD","BK4548","LU0316494557.USD","LU0456855351.SGD","LU1023059063.AUD","BK4588","BMY","BK4532","LU0868494617.USD","LU0114720955.EUR","LU0342679015.USD","LU1988902786.USD","BK4535","LU0237698245.USD","LU0528227936.USD","LU1670710588.SGD","LU1670711123.USD","LU1791710400.SGD","LU2041044095.USD","EVO.AU","LU2125154935.USD","LU1720051017.SGD","ANRO","LU1923622614.USD","LU2242652126.USD","LU1291159041.SGD","LU1670627923.USD","IE00BSNM7G36.USD","IE0009355771.USD","IE00B1BXHZ80.USD","LU0096362180.USD","LU1718418525.SGD","LU2092937221.SGD","TMO","BK4007","BK7132","LU1989771016.USD"],"gpt_icon":0},{"id":"2477058472","title":"Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2477058472","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477058472?lang=en_us&edition=fundamental","pubTime":"2024-10-23 20:47","pubTimestamp":1729687674,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/10/41487098/enphase-energy-posts-downbeat-results-joins-mcdonalds-seagate-and-other-big-stocks-moving-lower-in-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4504","LU1720051017.SGD","BK4535","LU1064131342.USD","LU0719512351.SGD","LU2357305700.SGD","LU0359202008.SGD","LU1430594728.SGD","BK4510","LU2294711713.HKD","BK4563","IE00BJTD4V19.USD","BK4503","BK4142","STX","LU2264538146.SGD","IE00BJJMRY28.SGD","BK4534","BK4588","LU1244550577.SGD","LU0823414478.USD","LU2506951792.HKD","BK4096","IE00BMPRXR70.SGD","BK4550","IE00BMPRXN33.USD","IE00B19Z9Z06.USD","BK4204","ENPH","BK4566","IE00B894F039.SGD","LU1988902786.USD","LU1718418525.SGD","LU0327786744.USD","LU2357125470.USD","MCD","IE00BJTD4N35.SGD","LU0359201612.USD","LU2249611893.SGD","LU0370786039.SGD","IE00BFSS8Q28.SGD","LU1023057109.AUD","HLT","LU0502904849.HKD","VRT","LU1093756168.USD","IE00BJJMRX11.SGD","ANRO"],"gpt_icon":1},{"id":"2477895735","title":"Investors Look Ahead to Economic Data as US Futures Decline Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2477895735","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477895735?lang=en_us&edition=fundamental","pubTime":"2024-10-23 20:13","pubTimestamp":1729685592,"startTime":"0","endTime":"0","summary":"US stock futures are moving lower in Wednesday's premarket session ahead of existing home sales figures, crude oil inventories, and a speech by Federal Reserve board member Michelle Bowman expected la","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4211","BK4588","ISBC","BK4147","LU1720051108.HKD","ENPH","BK4008","ANRO","US10Y.BOND","DBVT","LU0082616367.USD","LU0823414551.USD","LU1548497426.USD","LU2506951792.HKD","BK4153","LU0348723411.USD","BK4139","BK4585","LU1720051017.SGD","LU2357305700.SGD","CSTM","US5Y.BOND","LU1983299162.USD","SAVE","LU2294711713.HKD","BIVI","US7Y.BOND","US12M.BOND","US912797HE00.BOND","US30Y.BOND","US3Y.BOND","BK4500","BK4007","LU2249611893.SGD","US2Y.BOND","LU2357125470.USD","LU0719512351.SGD","LU0823414478.USD","US6M.BOND"],"gpt_icon":1},{"id":"2477583446","title":"Alto Neuroscience, Inc. (ANRO) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2477583446","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477583446?lang=en_us&edition=fundamental","pubTime":"2024-10-23 19:35","pubTimestamp":1729683318,"startTime":"0","endTime":"0","summary":"In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report), with a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alto-neuroscience-inc-anro-gets-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alto-neuroscience-inc-anro-gets-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","ANRO","BK4127","BK4007"],"gpt_icon":0},{"id":"2477758319","title":"Alto Neuroscience Is Maintained at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2477758319","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477758319?lang=en_us&edition=fundamental","pubTime":"2024-10-23 19:35","pubTimestamp":1729683300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 23, 2024 07:35 ET (11:35 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2477890307","title":"Alto Neuroscience downgraded to Neutral from Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2477890307","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477890307?lang=en_us&edition=fundamental","pubTime":"2024-10-23 18:51","pubTimestamp":1729680663,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw analyst Elemer Piros downgraded Alto Neuroscience (ANRO) to Neutral from Buy with a $5.50 price target Published first on TheFly –...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-downgraded-to-neutral-from-buy-at-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-downgraded-to-neutral-from-buy-at-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2477430420","title":"Alto Neuroscience price target lowered to $10 from $32 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2477430420","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477430420?lang=en_us&edition=fundamental","pubTime":"2024-10-23 18:30","pubTimestamp":1729679459,"startTime":"0","endTime":"0","summary":"Baird lowered the firm’s price target on Alto Neuroscience (ANRO) to $10 from $32 and keeps an Outperform rating on the shares. The firm lowered it...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-price-target-lowered-to-10-from-32-at-baird?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-price-target-lowered-to-10-from-32-at-baird?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2477371096","title":"Alto Neuroscience Says Phase 2b Study in Major Depressive Disorder Fails to Meet Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2477371096","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477371096?lang=en_us&edition=fundamental","pubTime":"2024-10-23 16:06","pubTimestamp":1729670780,"startTime":"0","endTime":"0","summary":"Alto Neuroscience  said late Tuesday a phase 2b study of ALTO-100 in patients with major depressive disorder failed to meet its primary endpoint compared with placebo.\"Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker,\" Alto Neuroscience said.ALTO-100 is also being evaluated as an adjunctive treatment in a phase 2b study for bipolar depression, the company said.Alto expects its current cash position to fund planned operations into 2027 and through multiple upcoming clinical readouts.Shares of the company plunged 60% in after-hours activity on Tuesday.Price: 5.82, Change: -8.71, Percent Change: -59.94","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2477391119","title":"Alto Neuroscience Shares Plunge After ALTO-100 Study Misses Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2477391119","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477391119?lang=en_us&edition=fundamental","pubTime":"2024-10-23 05:31","pubTimestamp":1729632660,"startTime":"0","endTime":"0","summary":"Shares of Alto Neuroscience have fallen to all-time lows in the after-hours market, following news a Phase 2 study of the company's ALTO-100 failed to meet its primary endpoint.After the bell, the stock had lost 63% and was trading at $5.36. Shares, which debuted in February, recorded their lowest intraday price of $7.91 on Aug. 12.Alto said its ALTO-100 treatment in patients with major depressive disorder failed to meet its primary endpoint in a Phase 2 study. The treatment didn't demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker, according to Alto.However, ALTO-100 did demonstrate a favorable safety and tolerability profile, which was consistent with earlier studies, the company said.Amit Etkin, the company's founder and chief executive officer, said Alto will evaluate the full data set and incorporate learnings set across its platform.The company said it expects its current cash position to fund planned operations ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALTO","BK4109","ANRO","BK4138"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":68,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANRO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.375,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ANRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ANRO","date":"2025-04-17","current":-0.991556,"percent":0.964664,"low":-16.978804,"twenty":-10.440317,"median":-6.19297,"eighty":-1.833785,"high":-0.793245,"avg":-5.903458,"sd":4.046455,"marketCap":60912290},"quantilePoints":[{"date":"2024-02-09","current":-15.481605,"twenty":-16.048587,"median":-15.481605,"eighty":-13.872658,"marketCap":506867732},{"date":"2024-02-16","current":-12.96931,"twenty":-15.548491,"median":-13.234406,"eighty":-11.571235,"marketCap":424615224},{"date":"2024-02-23","current":-10.603839,"twenty":-15.481605,"median":-12.585941,"eighty":-11.026361,"marketCap":347169680},{"date":"2024-03-01","current":-12.56147,"twenty":-14.292343,"median":-12.488059,"eighty":-11.135662,"marketCap":411262544},{"date":"2024-03-08","current":-11.631595,"twenty":-13.230328,"median":-12.361629,"eighty":-11.293904,"marketCap":380818433},{"date":"2024-03-15","current":-12.153631,"twenty":-13.001937,"median":-12.137317,"eighty":-11.306955,"marketCap":397909864},{"date":"2024-03-22","current":-11.14409,"twenty":-12.949734,"median":-12.108768,"eighty":-11.306955,"marketCap":404586204},{"date":"2024-03-28","current":-12.415912,"twenty":-12.956259,"median":-12.145474,"eighty":-11.437463,"marketCap":450759680},{"date":"2024-04-05","current":-10.418119,"twenty":-12.920369,"median":-11.868143,"eighty":-11.162905,"marketCap":378229815},{"date":"2024-04-12","current":-10.440317,"twenty":-12.863272,"median":-11.793418,"eighty":-10.823597,"marketCap":379035702},{"date":"2024-04-19","current":-9.988964,"twenty":-12.713187,"median":-11.631595,"eighty":-10.532067,"marketCap":362649325},{"date":"2024-04-26","current":-10.455115,"twenty":-12.538631,"median":-11.566341,"eighty":-10.461035,"marketCap":379572960},{"date":"2024-05-03","current":-10.654895,"twenty":-12.497847,"median":-11.513206,"eighty":-10.478793,"marketCap":386825947},{"date":"2024-05-10","current":-10.802879,"twenty":-12.4592,"median":-11.360121,"eighty":-10.478793,"marketCap":392198529},{"date":"2024-05-17","current":-8.114957,"twenty":-12.377436,"median":-11.191128,"eighty":-10.431438,"marketCap":344382544},{"date":"2024-05-24","current":-7.443985,"twenty":-12.295701,"median":-11.079356,"eighty":-10.270134,"marketCap":315907856},{"date":"2024-05-31","current":-7.59948,"twenty":-12.254775,"median":-10.943138,"eighty":-9.999323,"marketCap":322506720},{"date":"2024-06-07","current":-7.453823,"twenty":-12.218885,"median":-10.773282,"eighty":-9.088414,"marketCap":316325341},{"date":"2024-06-14","current":-7.612146,"twenty":-12.153631,"median":-10.654895,"eighty":-8.114957,"marketCap":323044231},{"date":"2024-06-21","current":-6.997854,"twenty":-12.14058,"median":-10.580902,"eighty":-7.890353,"marketCap":296974938},{"date":"2024-06-28","current":-6.731872,"twenty":-12.125897,"median":-10.558705,"eighty":-7.854905,"marketCap":285687202},{"date":"2024-07-05","current":-7.35883,"twenty":-12.080219,"median":-10.514309,"eighty":-7.738804,"marketCap":312294007},{"date":"2024-07-12","current":-8.486086,"twenty":-11.912764,"median":-10.492111,"eighty":-7.738804,"marketCap":360132504},{"date":"2024-07-15","current":-8.840728,"twenty":-11.90384,"median":-10.492111,"eighty":-7.738804,"marketCap":375182817},{"date":"2024-08-02","current":-6.212575,"twenty":-11.894916,"median":-10.481012,"eighty":-7.674208,"marketCap":263649243},{"date":"2024-08-09","current":-5.762939,"twenty":-11.86488,"median":-10.440317,"eighty":-7.584281,"marketCap":244567596},{"date":"2024-08-16","current":-5.077305,"twenty":-11.842621,"median":-10.421819,"eighty":-7.439715,"marketCap":252875166},{"date":"2024-08-23","current":-5.770157,"twenty":-11.798049,"median":-10.270134,"eighty":-7.320833,"marketCap":287382652},{"date":"2024-08-30","current":-6.766131,"twenty":-11.747422,"median":-10.066655,"eighty":-7.023186,"marketCap":336987162},{"date":"2024-09-06","current":-6.885215,"twenty":-11.696849,"median":-9.985264,"eighty":-6.997854,"marketCap":342918136},{"date":"2024-09-13","current":-7.036776,"twenty":-11.629964,"median":-9.589405,"eighty":-7.005638,"marketCap":350466649},{"date":"2024-09-20","current":-7.269531,"twenty":-11.615282,"median":-8.800669,"eighty":-7.041657,"marketCap":362059007},{"date":"2024-09-27","current":-6.495486,"twenty":-11.576129,"median":-8.327763,"eighty":-6.997854,"marketCap":323507676},{"date":"2024-10-04","current":-5.51575,"twenty":-11.542663,"median":-8.073812,"eighty":-6.792939,"marketCap":274711934},{"date":"2024-10-11","current":-6.392641,"twenty":-11.505807,"median":-7.947789,"eighty":-6.506312,"marketCap":318385471},{"date":"2024-10-18","current":-7.724215,"twenty":-11.453451,"median":-7.863613,"eighty":-6.586066,"marketCap":384704544},{"date":"2024-10-25","current":-2.23553,"twenty":-11.361501,"median":-7.821648,"eighty":-6.506312,"marketCap":111340558},{"date":"2024-10-31","current":-2.181401,"twenty":-11.357822,"median":-7.776801,"eighty":-6.403467,"marketCap":108644661},{"date":"2024-11-08","current":-2.083968,"twenty":-11.223755,"median":-7.738804,"eighty":-6.212575,"marketCap":103792046},{"date":"2024-11-15","current":-2.159604,"twenty":-11.191128,"median":-7.724215,"eighty":-6.11117,"marketCap":124062772},{"date":"2024-11-22","current":-1.92017,"twenty":-11.14409,"median":-7.634377,"eighty":-5.98126,"marketCap":110307987},{"date":"2024-11-29","current":-2.070403,"twenty":-11.113816,"median":-7.615312,"eighty":-5.768005,"marketCap":118938440},{"date":"2024-12-06","current":-1.830969,"twenty":-11.06322,"median":-7.574148,"eighty":-5.648645,"marketCap":105183655},{"date":"2024-12-13","current":-1.798105,"twenty":-11.000259,"median":-7.504253,"eighty":-5.44863,"marketCap":103295743},{"date":"2024-12-20","current":-1.746462,"twenty":-10.916697,"median":-7.443985,"eighty":-5.07514,"marketCap":100329024},{"date":"2024-12-27","current":-2.075098,"twenty":-10.841355,"median":-7.436869,"eighty":-2.363274,"marketCap":119208142},{"date":"2025-01-03","current":-2.056319,"twenty":-10.79104,"median":-7.390494,"eighty":-2.255016,"marketCap":118129335},{"date":"2025-01-10","current":-2.070403,"twenty":-10.767363,"median":-7.35883,"eighty":-2.165554,"marketCap":118938440},{"date":"2025-01-17","current":-2.079793,"twenty":-10.725927,"median":-7.312287,"eighty":-2.141345,"marketCap":119477844},{"date":"2025-01-24","current":-2.272279,"twenty":-10.654895,"median":-7.277651,"eighty":-2.138097,"marketCap":130535613},{"date":"2025-01-31","current":-2.093877,"twenty":-10.603839,"median":-7.253293,"eighty":-2.122046,"marketCap":120286949},{"date":"2025-02-07","current":-1.854443,"twenty":-10.580902,"median":-7.17813,"eighty":-2.093877,"marketCap":106532163},{"date":"2025-02-14","current":-1.530502,"twenty":-10.558705,"median":-7.145034,"eighty":-2.075098,"marketCap":87922747},{"date":"2025-02-21","current":-1.464775,"twenty":-10.529107,"median":-7.061183,"eighty":-2.070403,"marketCap":84146924},{"date":"2025-02-28","current":-1.305152,"twenty":-10.515789,"median":-6.997854,"eighty":-2.041295,"marketCap":74977067},{"date":"2025-03-07","current":-1.854443,"twenty":-10.50839,"median":-6.933931,"eighty":-2.023455,"marketCap":106532163},{"date":"2025-03-14","current":-1.483554,"twenty":-10.495071,"median":-6.768,"eighty":-2.01289,"marketCap":85225730},{"date":"2025-03-21","current":-1.180996,"twenty":-10.492111,"median":-6.549615,"eighty":-1.993408,"marketCap":72549751},{"date":"2025-03-28","current":-1.062067,"twenty":-10.474353,"median":-6.422411,"eighty":-1.971812,"marketCap":65243830},{"date":"2025-04-04","current":-0.81528,"twenty":-10.458075,"median":-6.392641,"eighty":-1.92017,"marketCap":50083438},{"date":"2025-04-11","current":-0.903418,"twenty":-10.443277,"median":-6.253891,"eighty":-1.873222,"marketCap":55497864},{"date":"2025-04-17","current":-0.991556,"twenty":-10.440317,"median":-6.19297,"eighty":-1.833785,"marketCap":60912290}],"updateTime":1745143804540}}}